Japan Severe Asthma Treatment Market was valued at USD 0.9 Billion in 2022 and is projected to reach USD 1.5 Billion by 2030, growing at a CAGR of 7.4% from 2024 to 2030.
The Severe Asthma Treatment Market in Japan is experiencing significant growth, driven by rising cases of asthma and advancements in targeted biologic therapies. Severe asthma, which is unresponsive to standard inhalers and corticosteroids, has led to a surge in demand for specialized treatments. The industry is witnessing an influx of innovative biologic drugs, precision medicine, and digital health solutions aimed at improving patient outcomes.
Japan’s healthcare system has been adapting to new severe asthma treatment options, with biologic therapies like monoclonal antibodies gaining traction. These therapies, including interleukin-5 (IL-5) and IgE inhibitors, have revolutionized severe asthma management by reducing exacerbations and improving lung function. The Japanese pharmaceutical industry is heavily investing in research and development to bring more targeted therapies to market.
Key pharmaceutical companies and biotech firms are focusing on personalized medicine, integrating genetic profiling to determine the most effective treatment for each patient. The demand for injectable biologics such as mepolizumab, benralizumab, and dupilumab is increasing due to their proven efficacy in reducing inflammation and hospitalizations.
With over 8 million asthma sufferers in Japan, approximately 5-10% have severe asthma, requiring advanced treatments beyond conventional inhalers. This has led to an increased need for biologic drugs, smart inhalers, and digital monitoring tools. The healthcare industry is also seeing greater adoption of artificial intelligence (AI) to predict asthma exacerbations and optimize treatment plans.
The regulatory landscape in Japan has facilitated the approval of novel severe asthma treatments, accelerating market growth. The Pharmaceuticals and Medical Devices Agency (PMDA) has streamlined approval pathways for biologics, allowing faster patient access. Japan’s universal healthcare system supports reimbursement policies, making innovative treatments more accessible to patients.
Hospitals and clinics are increasingly integrating digital tools such as telemedicine, remote monitoring, and AI-driven diagnostic tools to enhance asthma management. The demand for precision medicine, combined with AI-driven treatment algorithms, is shaping the future of the Severe Asthma Treatment Market in Japan. Industry players are focusing on improving patient adherence through connected devices and patient support programs.
The market is expected to grow at a robust rate due to rising environmental factors contributing to asthma severity, such as air pollution and climate change. Pharmaceutical firms are collaborating with research institutions to develop next-generation therapies aimed at providing long-term relief and improved quality of life for severe asthma patients.
Get an In-Depth Research Analysis of the Japan Severe Asthma Treatment Market Size And Forecast [2025-2032]
Â
Teva Pharmaceutical
AstraZeneca
GlaxoSmithKline
Novartis
Sanofi
Regeneron Pharmaceutical
4D Pharma plc
AB Pharma
Morphosys
Roche
Avalo Therapeutics
Suzhou Connect Biopharmaceuticals
Pieris Pharma
Biosion
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Severe Asthma Treatment Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Severe Asthma Treatment Market
Biologics
Oral Corticosteroids
Inhaled Corticosteroids
Long-Acting Beta Agonists (LABAs)
Short-Acting Beta Agonists (SABAs)
Leukotriene Modifiers
Immunomodulators
Inhalation
Oral
Injectable
Intranasal
Pediatrics (0-14 years)
Adolescents (15-18 years)
Adults (19-64 years)
Geriatrics (65+ years)
Intermittent Asthma
Persistent Asthma
Severe Persistent Asthma
Exercise-Induced Asthma
Anti-Inflammatory Agents
Bronchodilators
Anticholinergics
Biological Therapies (e.g., monoclonal antibodies)
Combination Therapies
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Severe Asthma Treatment Market Research Analysis
1. Introduction of the Japan Severe Asthma Treatment Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Severe Asthma Treatment Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Severe Asthma Treatment Market, By Type
6. Japan Severe Asthma Treatment Market, By Application
7. Japan Severe Asthma Treatment Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Severe Asthma Treatment Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/